🎥@PTarantinoMD of @DanaFarber highlights breast cancer updates at #ASCO23. Exciting results from NATALEE trial show ribociclib + endocrine therapy benefiting early breast cancer patients. Also discusses ADC sequencing in #BreastCancer:

➡️

#ASCO23 #BCSM

Breast cancer at ASCO 2023: NATALEE and sequencing ADCs

Paolo Tarantino, MD, Dana-Farber Cancer Institute, Boston, MA, provides an overview of key updates in breast cancer ...

ow.ly

🎥J. Randolph Hecht, MD, of @UCLAHealth explores IO in solid tumors at #ASCO2023. Exciting progress in tumor vaccines, with KRAS targeting showing immune response. Discusses CAR T-cell therapies, challenges of efficacy, and managing off-target toxicity:

➡️

Tumor vaccines, oncolytic viruses and CAR T

J. Randolph Hecht, MD, UCLA Santa Monica Medical Center, Santa Monica, CA, discusses immunotherapy approaches in solid...

ow.ly

🎥@jasonlukemd of @PittTweet presents key insights from the Phase III KEYNOTE-716 trial at #ASCO23. Exciting results show pembrolizumab's efficacy in high-risk cutaneous melanoma, redefining treatment options in the adjuvant setting:

➡️⬅️

#MelSM #SkcSM

KEYNOTE-716: pembrolizumab in stage 2B/2C cutaneous melanoma

Jason Luke, MD, FACP, University of Pittsburgh, Pittsburgh, PA, provides an overview of the Phase III KEYNOTE-716 (N...

ow.ly

🎥@JSabari of @nyulangone discusses latest updates in KRAS-mutant #NSCLC management at #ASCO23. Sotorasib shows improved survival in G12C mutation, while JDQ443 demonstrates promising efficacy as a novel KRAS inhibitor:

➡️⬅️

@ASCO #LungCancer #LCSM

What are the latest developments in KRAS-mutant NSCLC?

Joshua Sabari, MD, NYU Langone Health Perlmutter Cancer Center, New York, NY, comments on updates in the management ...

ow.ly